French biotech company Ipsen to buy Kartos Therapeutics for $450 million

June 29 (Reuters) – Ipsen will buy U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with a late-stage blood cancer treatment, the French biotech company said on Monday.

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)